Neuropsychiatrische Störungen bei idiopathischem Parkinson-Syndrom

ZUSAMMENFASSUNG

Unter nicht motorischen Symptomen nehmen neuropsychiatrische Störungen im gesamten Krankheitsverlauf eine herausragende Stellung ein. Sie sind nach wie vor unterdiagnostiziert, haben jedoch erhebliche Auswirkungen auf die Lebensqualität des Patienten und der Angehörigen. Einige Symptome können auf eine ungünstige Prognose verweisen. Die Mehrzahl der neuropsychiatrischen Störungen kann bei einer zielgerichteten klinischen Anamnese unter Einschluss der Angehörigen erfasst werden. Manchmal, z. B. bei kognitiven Defiziten, bedarf es einer neuropsychologischen Testung. Die Behandlung umfasst medikamentöse und nicht medikamentöse Maßnahmen. Allerdings gibt es nur relativ wenig Daten aus kontrollierten Studien, die die Wirksamkeit und Sicherheit einzelner Therapiemaßnahmen belegen.

ABSTRACT

Among non-motor symptoms neuropsychiatric disorders are highly prevalent throughout the course of Parkinson’s disease. They are still underrecognized but have a substantial impact on patient’s quality of life and caregiver burden. Some symptoms may precede adverse outcomes. Most neuropsychiatric symptoms can be revealed by a goal-driven clinical interview including information from the caregivers. In some disorders, e. g. cognitive deficits, neuropsychological testing is mandatory. Treatment includes pharmacological and non-pharmacological approaches. However, currently only a paucity of data from controlled studies support the efficacy and safety of certain therapies.

Schlüsselwörter

Parkinson-Syndrom - Neuropsychiatrie - Depression - Angst - Impulskontrollstörung - Demenz - Psychose

Key words

Parkinson’s disease - neuropsychiatry - depression - anxiety - impulse control disorder - dementia - psychosis

Publication History

Article published online:
05 October 2021

• Literatur

• 1 Aarsland D, Larsen JP, Tandberg E. et al Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48 (08) 938-942
• 2 Hely MA, Morris JG, Reid WG. et al Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199
• 3 Kalia LV, Lang AE. Parkinson’s disease. Lancet 2015; 386 9996 896-912
• 4 Pennington C, Duncan G, Ritchie C. Altered awareness of cognitive and neuropsychiatric symptoms in Parkinson’s disease and Dementia with Lewy Bodies: A systematic review. Int J Geriatr Psychiatry 2021; 36 (01) 15-30
• 5 Marsh L. Depression and Parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep 2013; 13 (12) 409
• 6 Su W, Liu H, Jiang Y. et al Correlation between depression and quality of life in patients with Parkinson’s disease. Clin Neurol Neurosurg 2021; 202: 106523
• 7 Wen MC, Chan LL, Tan LC. et al Depression, anxiety, and apathy in Parkinson’s disease: insights from neuroimaging studies. Eur J Neurol 2016; 23 (06) 1001-19
• 8 Prell T, Witte OW, Grosskreutz J. Biomarkers for Dementia, Fatigue, and Depression in Parkinson’s Disease. Front Neurol 2019; 10: 195
• 9 Shepard MD, Perepezko K, Broen MPG. et al Suicide in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2019; 90 (07) 822-829
• 10 Weintraub D, Duda JE, Carlson K. et al CSP 468 Study Group. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson’s disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2013; 84 (10) 1113-8
• 11 Storch A, Schneider CB, Wolz M. et al Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80 (09) 800-9
• 12 Seppi K, Ray Chaudhuri K. et al the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord 2019; 34 (02) 180-198
• 13 Menza M, Dobkin RD, Marin H. et al A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72 (10) 886-92
• 14 DGN. Leitlinien für Diagnostik und Therapie in der Neurologie. Idiopathisches Parkinson Syndrom. 2016; AWMF-Register-Nummer: 030–010 www.dgn.org
• 15 Takahashi M, Tabu H, Ozaki A. et al REBORN study group. Antidepressants for Depression, Apathy, and Gait Instability in Parkinson’s Disease: A Multicenter Randomized Study. Intern Med 2010; 58 (03) 361-368
• 16 Dobkin RD, Menza M, Allen LA. et al Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry 2011; 168 (10) 1066-74
• 17 Moonen AJH, Mulders AEP, Defebvre L. et al Cognitive Behavioral Therapy for Anxiety in Parkinson’s Disease: A Randomized Controlled Trial Mov Disord. 2021
• 18 Scheffels JF, Fröhlich L, Kalbe E. et al Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson’s disease. J Neurol Sci 2020; 412: 116735
• 19 Muslimovic D, Post B, Speelman JD. et al Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65 (08) 1239-45
• 20 Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci 2017; 374: 26-31
• 21 Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain 2015; 138 Pt 6 1454-76
• 22 Rolinski M, Fox C, Maidment I. et al Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012; 03: CD006504
• 23 Rothenberg KG, Rajaram R. Advances in Management of Psychosis in Neurodegenerative Diseases. Curr Treat Options Neurol 2019; 21 (01) 3
• 24 Mamikonyan E, Xie SX, Melvin E. et al Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord 2015; 30 (07) 912-8
• 25 Leung IH, Walton CC, Hallock H. et al Cognitive training in Parkinson disease: A systematic review and meta-analysis. Neurology 2015; 85 (21) 1843-51
• 26 Lenka A, Pagonabarraga J, Pal PK. et al Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications. Neurology 2019; 93 (06) 259-266
• 27 Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R. et al Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov Disord 2016; 31 (01) 45-52
• 28 Goetz CG, Leurgans S, Pappert EJ. et al Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology 2001; 57 (11) 2078-82
• 29 Barrett MJ, Smolkin ME, Flanigan JL. et al Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia. Parkinsonism Relat Disord 2017; 43: 56-60
• 30 Abbasi MH, Esmaeili S, Habibi SA. et al Dilemma in Parkinson’s Treatment; Levodopa Monotherapy May be the Best Choice. J Clin Neurosci 2020; 79: 219-223
• 31 Diederich NJ, Fénelon G, Stebbins G. et al Hallucinations in Parkinson disease. Nat Rev Neurol 2009; 05 (06) 331-42
• 32 Lizarraga KJ, Fox SH, Strafella AP. et al Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. Clin Geriatr Med 2020; 36 (01) 105-118
• 33 Oh YS, Kim JS, Lee PH. Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia. J Mov Disord 2015; 08 (02) 98-102
• 34 Zhang JF, Wang XX, Feng Y. et al Impulse Control Disorders in Parkinson’s Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. Front Psychiatry 2021; 12: 635494
• 35 Corvol JC, Artaud F, Cormier-Dequaire F. et al DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018; 91 (03) e189-e201
• 36 Jeon N, Bortolato M. What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson’s disease? A preliminary pharmacoepidemiologic study. PLoS One 2020; 15 (01) e0227128
• 37 Okai D, Askey-Jones S, Samuel M. et al Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson’s disease. Mov Disord 2015; 30 (05) 736-9